Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report issued on Monday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners cut their target price on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 6.6 %

Shares of NASDAQ AWH opened at $0.81 on Monday. Aspira Women’s Health has a twelve month low of $0.67 and a twelve month high of $5.65. The company has a 50 day moving average of $0.83 and a 200 day moving average of $1.27. The firm has a market cap of $13.50 million, a P/E ratio of -0.68 and a beta of 1.44.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.